However, thanks to the positive results from phase II and data suggesting that PSA-TRICOM vaccine may have greater efficacy in earlier-stage diseases [119], there have been several studies that continue testing this strategy in different settings: In a randomized phase II trial (NCT02326805), the National Cancer Institute is studying how well the PROSTVAC (prostate-specific antigen [PSA]-TRICOM) vaccine works in preventing disease progression in patients with prostate cancer undergoing active surveillance. The gene discussed is KLK3; the disease is prostate carcinoma.